Sumitomo Pharma Co (4506.T) Stock Price
Sumitomo Pharma Co Price
Over the last 19 years Sumitomo Pharma Co grew revenue by 2.9% annually, reaching 453.29 B JPY. Earnings per share have grown at 8.5% per year over the last 19 years. For Sumitomo Pharma Co, the net margin of 23.6% is up versus 10.1% a few years ago. At today's price the dividend yield works out to roughly 0.36%. The payout ratio is around 22% of earnings. The consensus 12-month price target for Sumitomo Pharma Co is 2,397.00 JPY, about 24.0% above where the stock trades today. Of 10 analysts, 6 rate the stock a buy — an overall Buy consensus.
Sumitomo Pharma Co stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Sumitomo Pharma Co business model & stock analysis
Frequently asked questions about Sumitomo Pharma Co
The business model of Sumitomo Dainippon Pharma Co Ltd revolves around the development, manufacturing, and commercialization of innovative pharmaceutical products. As a leading Japanese pharmaceutical company, Sumitomo Dainippon Pharma focuses on researching and providing solutions to significant unmet medical needs. By leveraging its expertise in various therapeutic areas, the company aims to improve patients' health and well-being while contributing to society. Sumitomo Dainippon Pharma actively collaborates with partners, both domestically and internationally, to enhance its global presence and deliver effective and safe treatments to a diverse range of patients.
Sumitomo Dainippon Pharma Co Ltd is primarily active in the pharmaceutical industry.
The main competitors of Sumitomo Dainippon Pharma Co Ltd in the market include Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., and Daiichi Sankyo Company, Limited.
Sumitomo Dainippon Pharma Co Ltd is a renowned pharmaceutical company with a rich history and background. Founded in 1897, it has evolved into a global leader in the healthcare industry. Sumitomo Dainippon Pharma focuses on the research, development, and commercialization of innovative pharmaceuticals across therapeutic areas such as neuroscience, oncology, and rare diseases. The company's commitment to improving patient outcomes and addressing unmet medical needs has driven its success. With a strong emphasis on scientific advancements and strategic collaborations, Sumitomo Dainippon Pharma continues to make significant contributions to the global pharmaceutical landscape.
Sumitomo Dainippon Pharma Co Ltd has achieved several significant milestones throughout its history. Notably, the company successfully developed and launched innovative psychiatric medications, such as LATUDA, which has contributed to the treatment of schizophrenia and bipolar disorder. Additionally, Sumitomo Dainippon Pharma Co Ltd expanded its global presence through strategic partnerships and acquisitions, enhancing its research and development capabilities. The company's dedication to advancing healthcare is evident in its commitment to exploring breakthrough therapies and collaborations with leading medical institutions worldwide. These achievements solidify Sumitomo Dainippon Pharma Co Ltd's position as a leading pharmaceutical company focused on improving the lives of patients through innovative treatments and transformative healthcare solutions.
Sumitomo Dainippon Pharma Co Ltd is primarily present in Japan.
Sumitomo Dainippon Pharma Co Ltd is a Japanese company that values innovation, integrity, and dedication to improving patient outcomes. The company's corporate philosophy is rooted in contributing to society through the discovery and development of innovative pharmaceuticals. Sumitomo Dainippon Pharma Co Ltd focuses on research and development to provide effective and safe medical solutions to patients worldwide. With a commitment to continuous growth and improvement, the company strives to enhance the quality of life for individuals and the community as a whole. Sumitomo Dainippon Pharma Co Ltd's corporate philosophy guides its mission to contribute to the health and well-being of society by delivering innovative and reliable pharmaceutical products.
Analysts currently set an average price target of 2,258.28 JPY for the Sumitomo Pharma Co stock (median: 2,397.00 JPY), implying +16.8 % versus the latest price. The consensus is based on 10 analyst ratings.
10 analysts currently rate the Sumitomo Pharma Co stock: 6 recommend buying, 3 holding and 1 selling.
Converted at the current exchange rate, the Sumitomo Pharma Co share trades at 10.89 EUR (1,933.50 JPY).
The Sumitomo Pharma Co share (4506.T) is listed on 5 stock exchanges, including: Tokio (JPX) (4506.T), Frankfurt (DPM.F), München (DPM.MU), Düsseldorf (DPM.DU).
Sumitomo Dainippon Pharma Co Ltd is a well-known Japanese pharmaceutical company that has been in existence since 1896 and is headquartered in Osaka. The company operates in many fields, including mental health, cancer, diabetes, and psychiatric disorders. The main business of Sumitomo Dainippon Pharma is drug development, manufacturing, and marketing. The company offers a wide range of products in various medical specialties, including flagship products such as "Cablivi," an innovative medication for the treatment of thrombotic thrombocytopenic purpura (TTP), and "Latuda," a medication used for the treatment of schizophrenia and bipolar disorders. Sumitomo Dainippon Pharma is also involved in the generic industry. Generics are imitations of brand-name drugs and usually have the same active ingredient content as the original product but are less expensive. The company offers a wide range of generics to meet the needs of patients worldwide. The company also covers the manufacturing and sale of diagnostic systems for clinical practice. The company also conducts preclinical and clinical trials for new drugs, including Holland chamber studies and phase I-IV studies for new drug developments to evaluate their safety and efficacy. In addition, Sumitomo Dainippon Pharma has integrated medical technology, also known as medical devices. The company invests in creative research to develop innovative medical devices that improve the quality of patients' health worldwide. These include diagnostic devices, medical devices, insulin cooling devices, and other medical devices. The company is also involved in the production and sale of cosmetic products, mainly including anti-aging products, skincare products, and makeup products. Several mergers and acquisitions have helped Sumitomo Dainippon Pharma expand its business into various areas in recent years. In 2010, the company expanded into the field of cancer research through the acquisition of Boston Biomedical. A year later, the company acquired Irish company Shionogi & Co Ltd. and entered the business of pharmaceuticals for psychiatric disorders. In 2018, Sumitomo Dainippon Pharma acquired Latin American company Companhia Brasileira de Distribuição Remedios and Midatech Pharma PLC, a company specialized in the development of drugs for rare and life-threatening diseases. Overall, the business model of Sumitomo Dainippon Pharma is very comprehensive and aims to provide a wide range of medical products and services to improve patients' lives. The company is committed to achieving growth and expansion through innovative research and development of new products, as well as through acquisitions and mergers.
The revenue of Sumitomo Pharma Co is 453.29 B JPY. This figure is based on current financial data and reflects the company's business performance.
The profit of Sumitomo Pharma Co is 106.87 B JPY. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Sumitomo Pharma Co is currently 7.88. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Sumitomo Pharma Co stock.
The price-to-sales ratio (P/S) of Sumitomo Pharma Co is currently 1.86. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Sumitomo Pharma Co stock.
The Eulerpool Quality Score for Sumitomo Pharma Co is 2/10.
The ISIN of Sumitomo Pharma Co is JP3495000006. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Sumitomo Pharma Co is 858257. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Sumitomo Pharma Co is 4506.T. The ticker symbol is used to trade Sumitomo Pharma Co shares on the stock exchange.
Sumitomo Pharma Co stock
Sumitomo Pharma Co Peer Group
Sumitomo Pharma Co Ticker
Sumitomo Pharma Co FIGI
All fundamentals and in-depth analysis of Sumitomo Pharma Co
Our stock analysis for Sumitomo Pharma Co stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Sumitomo Pharma Co. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.